loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations
Open ICICI 3-in-1 Account

Nifty MidSmall Healthcare Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Narayana Hrudayalaya Ltd. 13 Feb 2026 18:42 PM
Result PDF

Q3FY26 Quarterly Result Announced for Narayana Hrudayalaya Ltd.

Healthcare Facilities company Narayana Hrudayalaya announced Q3FY26 results

  • Revenue from operations: Rs 21,511.7 million against Rs 13,345.9 million during Q3FY25, change 61%.
  • PBT: Rs 1,503.56 million against Rs 2,195.46 million during Q3FY25, change -32%.
  • PAT: Rs 1,280.86 million against Rs 1,936.41 million during Q3FY25, change -34%.
  • EPS: Rs 6.24 for Q3FY26.

Result PDF

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q3FY26 results

  • Total Revenue from Operations was Rs 37,368 million, with YoY growth of 10.7%.
    • India sales were Rs 24,959 million, YoY growth of 5.5%.
    • International sales were Rs 12,157 million, with YoY growth of 26.6%.
  • Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs 8,280 million, resulting in an EBITDA margin of 22.2% vs 22.5% in Q3FY25. EBITDA grew by 9.0% YoY.
  • R&D expenses for Q3FY26 were Rs 1,390 million, or 3.7% of total revenue from operations, vs Rs 1,312 million in Q3FY25 at 3.9% of total revenue from operations.
  • Profit before tax (after exceptional item) was Rs 7,812 million, YoY growth of 6.9%.
  • Net Profit (after Non-Controlling interest) was Rs 6,360 million, YoY growth of 1.6%.
  • Exceptional item for the quarter includes the impact of Rs 528 million on a preliminary basis related to the notification by the Government of India regarding the four Labour Codes.
  • According to IQVIA (SSA) data, for Q3FY26:
    • The Company registered a growth of 9.8% YoY vs the Indian Pharmaceutical Market (IPM), which grew by 10.9%.
    • Acute segment reported growth of 8.6% vs IPM, which grew by 7.8%, 80 bps outperformance.
    • Chronic segment reported growth of 15.8% vs IP,M which grew by 15.6%, 18 bps outperformance.

Sandeep Singh, Managing Director, Alkem Laboratories, said: “This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment. With its significant presence in high-barrier markets, best-in-class R&D and manufacturing, and robust quality systems, Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular, along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become a meaningful growth pillar for the company.”

Vikas Gupta, CEO, Alkem, said: “In Q3, we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses. We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full-year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets.”

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q3FY26 results

Consolidated Financial Highlights:

  • Consolidated Net total Income up 7% at Rs 2,412.69 crore.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.15% in Q3FY26 as against @ 19.87% in Q3FY25.
  • Consolidated Net Profit at Rs 326.27 crore (after exceptional items) up 31%.
  • Exports Income up 13% at Rs 770.49 crore.

Standalone Financial Highlights:

  • Standalone Net total Income up 11% at Rs 1,863.00 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 26.09% in Q3FY26 as against @ 24.25% in Q3FY25.
  • Standalone Net Profit at Rs 303.45 crore (after exceptional items) up 13%.
  • Indian formulations income up 12% at Rs 984.00 crore.

Result PDF

Pharmaceuticals company Lupin announced Q3FY26 results

  • Gross Profit was Rs 52,224 million compared to Rs 38,970 million in Q3FY25, with a gross margin of 73.5%.
  • Personnel cost was 16.1% of sales at Rs 11,433 million compared to Rs 9,844 million in Q3FY25.
  • Manufacturing and other expenses were 27.3% of sales at Rs 19,366 million compared to Rs 16,959 million in Q3FY25.
  • Adjusted PBT at Rs 15,220 million at 21.4%, up 42.1% YoY from Rs 10,713 million in Q3FY25.
  • PBT (excluding exceptional items) is Rs 19,486 million at 27.4%.
  • We have provided net one-time exceptional items of Rs 4,266 million.
  • Investment in R&D for the quarter was Rs 5,352 million (7.5% of sales).

Nilesh Gupta, Managing Director, Lupin, said: “We are happy to deliver another quarter of strong growth led by our highest ever quarterly sales in the US and double-digit growth in India and all other regions. We are on track to deliver a strong close to FY26."

Result PDF

Pharmaceuticals company Natco Pharma announced Q3FY26 results

  • Consolidated total revenue of Rs 705.4 crore for Q3FY26 as against Rs 651.1 crore as of 31st December 2024.
  • EBITDA (including other income) for the quarter was at Rs 216.8 crore with margins at 30.7%.
  • Net profit for the period, on a consolidated basis was Rs 151.3 crore.
  • The Board of Directors have declared an interim dividend of Rs 1.5 per equity share of Rs 2 each during Q3FY26.
  • Revenue from associated company, Adcock Ingram holdings Ltd., South Africa, for the first half of their financial year ending Dec 31st, 2025, was Rs 2,464 crore at a profit after tax of Rs 198 crore.

Result PDF

Pharmaceuticals company Abbott India announced Q3FY26 results

  • Revenue: Rs 1,724.04 crore against Rs 1,614.28 crore during Q3FY25, change 7%.
  • PBT: Rs 508.98 crore against Rs 487.59 crore during Q3FY25, change 4%.
  • PAT: Rs 375.96 crore against Rs 360.78 crore during Q3FY25, change 4%.
  • EPS: Rs 176.92 for Q3FY26.

Result PDF

Pharmaceuticals company Wockhardt announced Q3FY26 results

Financial Highlights:

  • Revenue of Rs 888 crore in Q3FY26 compared to Rs 725 crore in Q3FY25 growth of 22%.
  • EBITDA of Rs 173 crore compared to Rs 100 crore in Q3FY25, growth of 72%.
  • Profit before tax Rs 67 crore for Q3FY26 as compared to Rs 21 crore in Q3FY25.
  • Profit after tax Rs 61 crore against Rs 20 crore during Q3FY25.

Business Highlights:

  • India Branded Business stood at Rs 146 crore in Q3FY26 with a growth of 28% compared to the previous year. The India Business growth was aided by a substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK), and the introduction of the Regenerative Derma segment.
  • UK region stood at Rs 343 crore in Q3FY26 with a growth of 15% compared to the previous year.
  • Emerging Markets region stood at Rs 264 crore in Q3FY26 with a growth of 48% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth.
  • Irish region stood at Rs 57 crore in Q3FY26 with a growth of 23% compared to the previous year.
  • The overall Biotech operations for the quarter stood at Rs 213 crore, recording a growth of 96% vs Q4FY25 and 38% vs Q2FY26. This robust achievement is fuelled by our Emerging Market biotech segment growing at > 50 % with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key markets like Thailand, Egypt, Algeria and LATAM. Our Domestic Biotech operations continues to grow at double digit pace and is poised for decent growth in the future.

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q3FY26 results

  • Revenue from Operations increased by 8.4% YoY to Rs 8,646 crore with growth in Europe and ARV.
  • US formulations revenue increased by 2.2% YoY to Rs 3,739 crore (USD 420 million).
  • Europe formulations revenue increased by 27.4% YoY to Rs 2,703 crore (EUR 261 million).
  • Growth Markets revenue remained flat YoY at Rs 865 crore (USD 97 million).
  • ARV revenue increased by 22.4% YoY to Rs 376 crore (USD 42 million).
  • EBITDA before R&D stood at Rs 2,163 crores with a margin of 25.0%.
  • EBITDA before Forex and Other Income stood at Rs 1,773 crore; EBITDA margin at 20.5%.
  • Research & Development (R&D, including depreciation) spend was Rs 409 crore, 4.7% of revenues.
  • Received final approval for 7 ANDAs from the USFDA (including 2 ANDAs previously tentatively approved, now receiving final approval).
  • Net Profit for the period stood at Rs 910 crore. (inclusive of one-time cost due to change in labour code of Rs 65 crore).
  • Strong net cash position as on 31-Dec-25 after appropriating cash for the acquisition of Khandelwal laboratories is at USD 251 million.
  • Free Cashflows of USD 118 million generated during the quarter • Basic & Diluted EPS stood at Rs 15.67 per share.

K. Nithyananda Reddy, Vice-Chairman & Managing Director, said: “Q3 reflected steady execution across Aurobindo’s core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the U.S. and Europe. Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability. As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q3FY26 results

  • Revenue: Rs 447.8 lakh against Rs 401.9 lakh during Q3FY25, change 11%.
  • EBITDA: Rs 85 lakh against Rs 90.3 lakh during Q3FY25, change -6%.
  • EBITDA Margin: 19% for Q3FY26.
  • PBT: Rs 54.3 lakh against Rs 127.5 lakh during Q3FY25, change -57%.
  • PBT Margin: 12.1% for Q3FY26.
  • PAT: Rs 40.4 lakh against Rs 101.4 lakh during Q3FY25, change -60%.

Sucheth Davuluri, Vice-Chairman & Chief Executive Officer, said: “The revenues this quarter are in line with the outlook we envisaged for the year, however the product mix within businesses as well as increased operating expenses, is reflected in subdued EBITDA margins. We continue to see good momentum in the business which is driving our investments with the long-term in view, ensuring Neuland can take advantage of the number of growth opportunities.”

Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “We are seeing increasing interest from a wider range of customers interested in our capabilities as a proven commercial NCE drug substance manufacturer as well as an integral partner in the innovation journey. Our investments are leading to more engagements with existing customers while also attracting new customers who are looking for specific niche capabilities.”

Result PDF

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q3FY26 results

  • Revenue: Rs 1,04,126 lakh against Rs 94,942 lakh during Q3FY25, change 10%.
  • PBT: Rs 39,993 lakh against Rs 30,810 lakh during Q3FY25, change 30%.
  • PAT: Rs 29,562 lakh against Rs 22,988 lakh during Q3FY25, change 29%.
  • EPS: Rs 16.54 for Q3FY26.

Bhushan Akshikar, Managing Director, GSK India, said: “By moving immunotherapy from later lines to initial standard of care, the RUBY-1 trial has established a new paradigm in first-line treatment of endometrial cancer, and is now approved for this indication in India. The positive results on progression-free survival and overall survival in the population under trial will simplify decision-making for HCPs on treatment lines and benefit a wide range of endometrial cancer patients. Supported by comprehensive patient support and financing initiatives, the Company is leaving no stone unturned to ensure patients with cancer receive the highest standard of care.”

Result PDF

Trending News

Royal Enfield launches new Hunter 350 variant with upgrades

In a press release, Royal Enfield has expanded its 2026 Hunter 350 lineup with the launch of a new Base Premium variant and two new colour options—Mumbai Yellow and Moonshot White—targeted at urban riders. 

Published on 06-Apr-2026 09:29

Axis Bank reports 18.4% YoY growth in gross advances

Axis Bank reported healthy business growth in Q4FY26, with gross advances (end balance) rising to ₹12,44,200 crore, up 18.4% YoY (6.3% QoQ). 

Published on 06-Apr-2026 09:28

HDFC Bank sees 12% YoY growth in gross advances

HDFC Bank reported provisional business numbers in Q4FY26, with gross advances (period-end) rising to ₹29.60 lakh crore, up 12.0% YoY (4.1% QoQ). 

Published on 06-Apr-2026 09:27

Wipro wins $1 billion deal with Olam Group

Wipro has secured an 8-year strategic transformation deal with Singapore-based food and agri-business major Olam Group, with total contract value expected to exceed $1 billion, including a committed spend of $800 million. 

Published on 06-Apr-2026 09:26

Adani Ports sees 11% YoY growth in cargo handled to 500.8 MMT

Adani Ports saw 46 MMT of cargo handled  in March 2026 a 11% (including NQXT) growth on a YoY basis. This was led by containers which grew 14% YoY. For FY26 the total cargo handled grew 11% YoY to 500.8 MMT. 

Published on 06-Apr-2026 09:25

Kotak Mahindra Bank Q4FY26: Advances Rise 16.2% to ₹4.96L Cr, Deposits Grow 14.7% to ₹5.72L Cr

Kotak Mahindra Bank reported healthy business growth in Q4FY26, with net advances (EOP) rising 16.2% YoY (3.2% QoQ) to ₹4,95,892 crore as of March 31, 2026. 

Published on 06-Apr-2026 09:24

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app